Denise Scots-Knight
CIK 1297000 · Chief Executive Officer · last filed 2026-05-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.59M
Companies
5
Total Filings
41
Lifetime Open-Market Net
-$844.9K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ELAN | Director | 105,588 | $22.12 | $2.34M | $0 | 6 | 2026-05-26 |
| MREO | Chief Executive Officer | 868,967 | $0.30 | $257.5K | -$844.9K | 7 | 2026-02-02 |
| Elanco Animal Health Inc (ELAT) Delisted | Director | 39,857 | $21.32 | $849.8K | $0 | 3 | 2022-12-02 |
| ALBIREO PHARMA, INC. (ALBO) Delisted | Director | 1,165,447 | $44.15 | $51.45M | $0 | 3 | 2017-06-20 |
| IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Director | — | — | — | $0 | 8 | 2014-08-05 |
Recent Filings · Page 4 of 5
41 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-12-05 | — | Sell (S) | −25,000 | -$540.0K | |
| 2014-08-05 | IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Disp (D) | — | $0 | EDGAR |
| 2014-07-02 | — | Sell (S) | −11,485 | -$270.9K | |
| 2013-07-23 | — | Mixed | +2,122,807 | $1.00M | |
| 2013-06-10 | IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-06-11 | IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-06-03 | IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2010-06-04 | IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2009-06-03 | IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-06-04 | IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.